Mergers and Acquisitions

Date: 2022-04-11

Type of information: Company acquisition

Acquired company: Vibalogics (USA - MA)

Acquiring company: Recipharm (Sweden)

Amount: undisclosed


Recipharm announced the closing of its acquisition of virotherapy CDMO Vibalogics. The acquisition reflects Recipharm’s strategy of building its presence in the Biologics market, with a particular focus on drug substance manufacturing of novel ATMPs (advanced therapy medicinal products). They follow Recipharm’s entry into biologics earlier this year with the acquisition of Portuguese company GenIbet. The acquisitions also enable Recipharm to establish a robust base in the US, with facilities in Boxborough, MA, and provide a platform from which to build its capabilities in new biologics modalities. The deal will provide Recipharm with capabilities in new biologics modalities, leveraging Vibalogics’ expertise in oncolytic viruses, viral vaccines, and viral vector gene therapies to bring a high degree of diversification across multiple technologies and modalities. Vibalogics builds on the capabilities acquired through the recently announced GenIbet transaction and the acquisition of Arranta Bio.
Centerview Partners UK LLP acted as exclusive financial adviser, and Kirkland & Ellis LLP served as counsel to Recipharm on the transaction. Morgan Stanley & Co. LLC acted as exclusive financial advisor and Goodwin Procter LLP served as counsel to Vibalogics.


Vibalogics is responding to the rapidly growing biopharmaceutical industry demand for specialized CDMO capabilities for the manufacture of live viruses and viral vectors including Herpes Viruses, Pox Viruses, Adenoviruses, and other viral classes for cancer and other applications. The company has seen rapid growth of its global customer base comprised of Big Pharma, mid-sized biotechs and start-ups requiring its unusual process expertise, capabilities and capacity for virus production. Continued investment, including its recent expansion in Germany and the US, has positioned Vibalogics to support the full product lifecycle of its clients, including commercial supply.


Is general: Yes